Orthofix International N.V. (OFIX) Position Reduced by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. lessened its stake in Orthofix International N.V. (NASDAQ:OFIX) by 23.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 130,060 shares of the medical device company’s stock after selling 39,083 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.72% of Orthofix International N.V. worth $6,046,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of OFIX. Nationwide Fund Advisors increased its holdings in Orthofix International N.V. by 94.7% in the 1st quarter. Nationwide Fund Advisors now owns 24,441 shares of the medical device company’s stock worth $932,000 after acquiring an additional 11,888 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Orthofix International N.V. by 122.5% during the 1st quarter. Bank of New York Mellon Corp now owns 242,068 shares of the medical device company’s stock worth $9,236,000 after purchasing an additional 133,281 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Orthofix International N.V. by 68.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 4,656 shares of the medical device company’s stock worth $178,000 after purchasing an additional 1,900 shares during the last quarter. Comerica Bank acquired a new stake in Orthofix International N.V. during the 1st quarter worth $783,000. Finally, UBS Asset Management Americas Inc. acquired a new stake in Orthofix International N.V. during the 1st quarter worth $229,000. 94.40% of the stock is owned by institutional investors.

Several brokerages have issued reports on OFIX. BidaskClub raised shares of Orthofix International N.V. from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Zacks Investment Research raised shares of Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a research note on Thursday, August 10th. Jefferies Group LLC reaffirmed a “buy” rating and set a $55.00 target price (up previously from $50.00) on shares of Orthofix International N.V. in a research note on Thursday, August 10th. TheStreet raised shares of Orthofix International N.V. from a “c+” rating to a “b-” rating in a research note on Tuesday, August 8th. Finally, BTIG Research began coverage on shares of Orthofix International N.V. in a research note on Wednesday, June 21st. They set a “buy” rating and a $52.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $52.75.

TRADEMARK VIOLATION WARNING: This piece was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/10/11/orthofix-international-n-v-ofix-position-reduced-by-schwab-charles-investment-management-inc.html.

Shares of Orthofix International N.V. (NASDAQ OFIX) opened at 49.02 on Wednesday. The firm’s 50-day moving average is $48.72 and its 200 day moving average is $44.37. The firm has a market cap of $890.69 million, a PE ratio of 114.80 and a beta of 0.20. Orthofix International N.V. has a 52 week low of $32.51 and a 52 week high of $51.09.

Orthofix International N.V. (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The business had revenue of $108.90 million during the quarter, compared to analysts’ expectations of $102.94 million. During the same quarter last year, the business posted $0.41 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities research analysts forecast that Orthofix International N.V. will post $1.56 EPS for the current year.

In other news, CFO Rice Doug sold 7,353 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the transaction, the chief financial officer now owns 44,743 shares in the company, valued at $2,212,988.78. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Raymond Fujikawa sold 6,364 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $47.06, for a total value of $299,489.84. Following the completion of the transaction, the insider now owns 31,084 shares of the company’s stock, valued at approximately $1,462,813.04. The disclosure for this sale can be found here. In the last 90 days, insiders sold 23,406 shares of company stock valued at $1,138,531. Company insiders own 5.60% of the company’s stock.

Orthofix International N.V. Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).

Institutional Ownership by Quarter for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply